<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00956553</url>
  </required_header>
  <id_info>
    <org_study_id>HPV CSP01</org_study_id>
    <nct_id>NCT00956553</nct_id>
  </id_info>
  <brief_title>Reactogenicity Study of Cervarix and Gardasil in UK Adolescent Girls</brief_title>
  <acronym>HPV CSP01</acronym>
  <official_title>A Phase IV, Randomised Study to Evaluate the Immune Responses of UK Adolescent Girls Receiving CervarixTM or GardasilTM Human Papillomavirus Vaccines</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prof. Elizabeth Miller</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Public Health England</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase IV study to evaluate the body's immune response of participants to the
      Cervarix and Gardasil vaccines against the Human Papilloma Virus (HPV) types associated with
      increased risk of cervical cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study looks at possible cross reactivity between different HPV serotypes and both
      peripheral antibodies and mucosally-secreted antibodies.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurable antibody mediated neutralisation of HPV serotype 6, 11, 16, 18 and genetically related serotypes, especially 45</measure>
    <time_frame>18 months from enrollment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine differences in vaccine formulation and their impact on cross protection.</measure>
    <time_frame>24 months from enrollment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>HPV Infections</condition>
  <arm_group>
    <arm_group_label>Cervarix</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of Cervarix at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gardasil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three doses of Gardasil at month 0, 1 and 6. Blood sample at month 0, 2, 7 and 12. Optional vaginal sponge sample at month 7.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Cervarix</intervention_name>
    <description>Three doses of Cervarix at month 0, 1 and 6.</description>
    <arm_group_label>Cervarix</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Gardasil</intervention_name>
    <description>Three doses of Gardasil at month 0, 1 and 6.</description>
    <arm_group_label>Gardasil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Aged between 13 and 15 years at the time of the first immunisation

          -  Female

          -  No contraindications to vaccination as specified in the &quot;Green Book&quot; - Immunisation
             Against Infectious Disease, HMSO.

          -  Written informed consent obtained from parent or guardian of subject

        Exclusion Criteria:

          -  Pregnant or become pregnant during the course of the trial (no contraindications to
             vaccination for those taking the contraceptive pill).

          -  Breast-feeding mothers

          -  Allergic to vaccine components
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Health Protection Agency</name>
      <address>
        <city>Stevenage</city>
        <state>Hertfordshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Professor Elizabeth Miller</name>
      <address>
        <city>Gloucester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Health Protection Agency</name>
      <address>
        <city>London</city>
        <zip>NW9 5HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>http://www.hpa.org.uk</url>
    <description>Health Protection Agency main website. Type 'Clinical Trials' into the search bar to go to the clinical trials page.</description>
  </link>
  <verification_date>March 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 10, 2009</study_first_submitted>
  <study_first_submitted_qc>August 10, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 11, 2009</study_first_posted>
  <last_update_submitted>March 19, 2014</last_update_submitted>
  <last_update_submitted_qc>March 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 20, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Public Health England</investigator_affiliation>
    <investigator_full_name>Prof. Elizabeth Miller</investigator_full_name>
    <investigator_title>Prinicipal Investigator</investigator_title>
  </responsible_party>
  <keyword>HPV</keyword>
  <keyword>Human Papilloma Virus</keyword>
  <keyword>Cervical cancer vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Papillomavirus Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

